Health Condition 1: L408- Other psoriasis
Conditions
Interventions
Intervention1: Oral tablet: Oral tablet will be given in Group A Oral Methotrexate (0.3 mg/kg/week not exceeding 25 mg/week) once a week and Group B will be given Oral Tofacitinib (5 mg twice a day) f
Sponsors
Dr Gantvya Krishna
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient with Palmoplantar Psoriasis confirmed by clinical correlation, dermoscopy or biopsy proven in doubtful cases. 2. Patient?s of either sex of age group 18-65 years. 3. Patients not on any other systemic medication for the same for atleast 2 months or topical treatment for the same for past 1 month.
Exclusion criteria
Exclusion criteria: 1. Patient having any co-morbidity such as metabolic syndrome, hypertension, diabetes mellitus, cardiovascular disease, depression, and autoimmune disease. 2. Pregnant or breast feeding women. 3. History of TB or any contact with patient of TB. 4. History of active infection like chronic liver disease, cirrhosis, HIV/AIDS, renal dysfunction or blood disorders. 5. Previous hypersensitivity recorded to Tofacitinib/methotrexate. 6. Any other dermatitis on palm and sole. 7. Patients on immunosuppressive therapy like azathioprine, cyclosporine, mycophenolate mofetil, etc for any other medical condition. 8. Patient on concomitant medications such as ketoconazole, fluconazole, rifampicin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the efficacy of oral tofacitinib versus oral methotrexate in case of palmoplantar psoriasis.Timepoint: one year | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the safety of oral tofacitinib versus oral methotrexate in case of palmoplantar psoriasis.Timepoint: one year | — |
Countries
India
Contacts
Public ContactDr Gantvya Krishna
Jawaharlal Nehru Medical College, Belagavi
Outcome results
None listed